Primary source: R1 via GlobeNewswire, November 12, 2026, 8:00 a.m. ET. The same wire is on The Manila Times.
On November 12, 2026, R1 expanded Phare OS to six connected modules and put Phare Denials on the market. If you work the denial queue, that module is the one you can buy today. The loop that writes a payer’s reason back into the next claim still depends on modules that are not all for sale.
R1’s figure for net patient revenue now on Phare OS. In the past six months, health systems representing approximately $95 billion in NPR adopted individual modules for claim accuracy and utilization management, including UF Health and Guthrie Clinic’s adoption of Phare UM. That is the sentence that brings the total to more than $275 billion. This article does not subtract one figure from the other.
The item is datelined Chicago, November 12, 2026, and timed at 8:00 a.m. ET on GlobeNewswire. The source line is R1 RCM Holdco Inc. R1 calls Phare OS its revenue operating system and says the six modules are designed to bring agentic automation across the revenue cycle. “Agentic” is R1’s word.
| The November 12 release says | The release does not say |
|---|---|
| Six modules. Four are commercially available today: Phare Auth (prior authorization), Phare Audit (claim accuracy), Phare UM (utilization management), and new Phare Denials (denial management and appeals). Phare CDI (clinical documentation integrity) and Phare Recovery (post-payment revenue recovery) are in early access with select customers. Broader availability is planned for 2027. | A price, a yield share, or which result “outcome-based pricing” is tied to. The phrase is in the subhead. No rate, metric, or contract term is printed. |
| Phare Auth is now powered by Humata, following the recent closing of R1’s acquisition of Humata Health. | A close date, a purchase price, or any Humata performance rate. Those are not in this release. |
| Phare Denials automates technical and clinical denials, from early identification and evidence gathering through appeal creation and submission. It is meant to raise capacity and leave experts on complex, high-value cases. | An overturn rate, a recovered dollar, a cycle time, or a customer count for Phare Denials. |
| When paired with the full Phare OS, Phare Denials builds the intelligence behind the original determination into each appeal. Payer decisions and denial patterns can then inform pre-bill workflows. | That a Denials purchase by itself includes CDI or Recovery. The “full Phare OS” sentence is conditional. CDI and Recovery are the early-access modules. |
| More than $275 billion in net patient revenue is on Phare OS. Approximately $95 billion in NPR adopted claim-accuracy and utilization-management modules in the past six months, including UF Health’s collaboration on AI-Powered Revenue Cycle Transformation and Guthrie Clinic’s recent adoption of Phare UM. | That the $95 billion sits on top of the $275 billion, or that either figure is a Phare Denials book of business. The $95 billion is claim accuracy and UM. |
| Reopened claims, carrying costs and rework, consume approximately $28 million annually for every $1 billion in Medicare Advantage payments. R1 labels this proprietary R1 research. | That $28 million is a Phare Denials result, a customer outcome, or an audited national total. |
| 68.7% of healthcare organizations run six or more revenue cycle management vendors or platforms. 3.8% report a fully unified and orchestrated environment. R1 labels this new IDC research, sponsored by R1. | That installing Phare OS removes the other vendors. The release says a health system can start with one challenge and add modules, with its own teams or R1’s. |
| Geoff Gardner, UF Health’s chief financial officer, says Phare Audit aligns with existing coding on more than 95% of inpatient discharges, so experts can concentrate on the fewer than 5%. | A denial rate. The 95% is a coding-alignment figure for Phare Audit at one health system. It is not a Phare Denials result. |
| Payer Atlas draws on more than 1.25 billion payer transactions processed in 2026 and monitors more than 115,000 payer policies in real time. The shared foundation is Data Platform, Phare Intelligence, and Payer Atlas. | A policy-match rate, or a count of policies that changed. The About section separately says R1 handles over 1.25 billion payer transactions annually. That is a second sentence, not a second census. |
| R1 will show the portfolio at HLTH 2026, November 15–18 in Las Vegas, booth 4057. On November 16, Lee Kupferman speaks at 2:40 p.m. in AI Theater A. R1 joins Ascension Chief Revenue Officer James Logsdon at 3:40 p.m. in AI Theater C. | That the November 9 Ascension renewal now covers all six modules. Logsdon is on a panel. The renewal is a different release. |
“In this margin environment, we have to be deliberate about where we deploy our most skilled people,” said Geoff Gardner, UF Health’s chief financial officer. “Phare Audit aligns with our existing coding on more than 95% of inpatient discharges, so our experts can concentrate on the fewer than 5% of accounts that merit a closer look. That’s a more disciplined path to revenue integrity. Phare OS gives us a platform we can scale across the revenue cycle, so the return extends well beyond a single use case.”
“We’ve established Phare OS as the foundation for a different model of revenue management where technology isn’t measured by how many tasks it automates, but by the results it delivers,” said Joe Flanagan, chief executive officer of R1. “After decades of helping providers navigate the complexity of revenue cycle, we know what it takes to improve performance. We’re bringing that expertise together with AI and payer intelligence, and we stand behind the outcomes. This is the level of accountability health systems should expect from their revenue management partners.”
Gardner’s rate is the only operating percentage in the release, and he attaches it to Phare Audit. Flanagan’s line is the commercial promise: results, not task counts, and R1 stands behind the outcomes. The subhead is where outcome-based pricing is named. Neither the quote nor the subhead says which outcome, what share of it is R1’s, or what happens when the outcome misses.
Four modules are commercially available: Auth, Audit, UM, and Denials. CDI and Recovery are in early access, with broader availability planned for 2027. The $28 million is R1’s own research on reopened Medicare Advantage claims. The 68.7% and the 3.8% are IDC research sponsored by R1. Gardner’s 95% is coding alignment on inpatient discharges, for Phare Audit. None of those is an overturn rate for the new denials module. No fee was disclosed, and none is estimated here.
This is RevCycleAI’s read. Sold on its own, Phare Denials is a denial-lifecycle product: find the denial early, gather the evidence, write the appeal, submit it, for technical and clinical denials. The sentence operators will actually use is the conditional one. “When paired with the full Phare OS,” the appeal is supposed to contain the intelligence behind the original determination, and denial patterns are supposed to inform the work before the next claim goes out. CDI, the documentation module, is not generally available. Recovery, the post-payment module, is not generally available. A contract for the four modules on sale this week is Auth, UM, Audit, and Denials. It is not the six-module loop the headline describes.
Humata is the auth engine in this release, and only the auth engine. R1 says the Humata Health acquisition has closed and that Phare Auth is now powered by Humata. RevCycleAI covered the agreement to buy Humata, and to place prior-authorization automation inside Phare OS, when it was announced in August. Today’s release does not restate the performance figures from that announcement, and this article does not import them. Humata’s November 10 provisional affirmations are a WISeR result on an Oklahoma Medicare book, plus a same-day Humana oncology exemption with Evolent and American Oncology Network. A WISeR yes is not a Phare Auth result, and it is not a Phare Denials result.
The number you can take to a Medicare Advantage meeting is the $28 million, with the label attached. R1’s proprietary research says reopened claims, carrying costs and rework, consume approximately $28 million a year for every $1 billion in Medicare Advantage payments. Net patient revenue on Phare OS is a different denominator. More than $275 billion of NPR is not a Medicare Advantage book, and this article does not turn it into a reopened-claim total.
The IDC figures, which R1 sponsored, are the vendor-count argument. R1 says 68.7% of organizations run six or more RCM vendors or platforms, and 3.8% report a fully unified and orchestrated environment. R1’s product answer is six modules on one operating system. The same release says you can start with the revenue cycle challenge that matters most, prove value, and add connected capabilities over time, using your own teams or R1’s operational expertise. That is a modular sale. It does not say the other platforms come out. Six modules from one company can still sit beside the stack the IDC number describes.
Payer Atlas is the shared file R1 says every module draws on: more than 1.25 billion payer transactions processed in 2026, and more than 115,000 payer policies monitored in real time. The About section, separately, says R1 partners with 1,000 providers, including 95 of the top 100 U.S. health systems, and handles over 1.25 billion payer transactions annually, with more than 20 years of experience. Same order of magnitude, two sentences. The November 9 Ascension renewal used “more than 1.2 billion” in that release’s About section. Today’s About section says over 1.25 billion annually. This article does not merge them into one count.
Guthrie Clinic is named for a recent Phare UM adoption, inside the $95 billion sentence. RevCycleAI covered the Phare UM launch on September 16. Today’s release does not republish that launch’s metrics, and they are not repeated here as a Guthrie result. UF Health is named for a collaboration on AI-Powered Revenue Cycle Transformation, and Gardner’s quote is about Phare Audit. Ascension’s chief revenue officer is on the November 16 HLTH agenda. The November 9 renewal runs through fiscal 2037, and the contract value was not disclosed then either. A panel is not an amendment.
R1 is selling four Phare OS modules now, including a new denials product, against more than $275 billion of net patient revenue it says is already on the OS. The closed loop from the appeal back into documentation is the module still in early access. The $28 million per $1 billion of Medicare Advantage payments is R1’s research. The 68.7% running six or more vendors is IDC research R1 sponsored. Neither number is a Phare Denials result, and no price was disclosed.
Ask which four, or which six, are in the order. Auth is Humata, and this release says that acquisition has closed. Audit is the module with the only operating rate in the document, Gardner’s coding alignment at UF Health. UM is the module Guthrie just adopted, on R1’s account. Denials is new and commercially available, and it manages technical and clinical denials through appeal submission. CDI and Recovery are early access, with broader availability planned for 2027. Outcome-based pricing is named and not defined.
If you are in a renewal, the question is whether the appeal packet receives the auth and UM determination or only the claim as billed, and whether the fee is tied to overturns, prevented denials, or cash. The release does not pick. Flanagan says R1 stands behind the outcomes. The outcomes are not listed.
What is for sale, what is still early access, and whose research the big number is.
Sources: R1 via GlobeNewswire, “R1 Takes Aim at Healthcare’s Fragmented Revenue Cycle with Six Connected AI Solutions,” November 12, 2026, 8:00 a.m. ET, Chicago, source R1 RCM Holdco Inc. (page opened). The same wire was opened on The Manila Times. Quotes from Geoff Gardner and Joe Flanagan are verbatim from the GlobeNewswire release. Module names, availability, the Humata closing sentence, the $275 billion and approximately $95 billion NPR figures, the approximately $28 million Medicare Advantage research line, the 68.7% and 3.8% IDC lines, the Payer Atlas transaction and policy counts, the About-section scale figures, and the HLTH schedule are the release’s. “Approximately $28 million” and the IDC percentages are labeled in the release as proprietary R1 research and as IDC research sponsored by R1. The About section’s “over 1.25 billion payer transactions annually” and Payer Atlas’s “more than 1.25 billion payer transactions processed in 2026” are left as two sentences. No price was disclosed, and none is estimated. Prior RevCycleAI articles linked above are earlier events. They are not results of this launch. The analysis section is RevCycleAI’s read.